MN-166 is used for certain neurological conditions, including progressive forms of multiple sclerosis, neuropathic pain, and drug addiction.
The patent once received is expected to expire by the end of 2025 and covers a method of treating certain existing chronic neuropathic pain conditions by administering ibudilast either alone or in combination with other active ingredients.
MediciNova president and chief executive officer Yuichi Iwaki said the company is encouraged with the continuing expansion of use and composition exclusivity around its ibudilast and related analog program.